197894-84-1
![197894-84-1 结构式](https://img.chemicalbook.com/CAS/20200515/GIF/197894-84-1.gif)
197894-84-1 性质
沸点 | 773.2±60.0 °C(Predicted) |
---|---|
密度 | 1.43±0.1 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:125 mg/mL(314.52 mM) |
酸度系数(pKa) | 11.27±0.40(Predicted) |
形态 | 固体 |
颜色 | 浅黄至黄色 |
197894-84-1 用途与合成方法
PDE4A5 0.29 μM (IC 50 ) |
PDE4B2 0.08 μM (IC 50 ) |
PDE4C2 0.56 μM (IC 50 ) |
PDE4D3 0.09 μM (IC 50 ) |
CI-1044 is an orally active PDE4 inhibitor with IC 50 s of 0.29, 0.08, 0.56, 0.09 μM for PDE4A5, PDE4B2, PDE4C2 and PDE4D3, respectively. CI-1044 selectively inhibits PDE4 crude extract from U937 cells with an IC 50 value of 0.27±0.02 μM being threefold more potent than rolipram (IC 50 =0.91±0.14) and tenfold less potent than cilomilast (IC 50 =0.026±0.007) in the same assay. In the presence of PDE4 inhibitors, the production of TNF-α is dose dependently decreased with mean IC 50 values from three separate experiments of 0.31±0.05, 0.26±0.05 and 0.11±0.01 μM, for CI-1044, cilomilast and rolipram, respectively.
TNF-α production is dose-dependently inhibited by CI-1044, rolipram and cilomilast with ID 50 s of 0.4, 1.4 and 1.6 mg/kg respectively following single oral administration. Following repeated administration with CI-1044, the ID 50 value represents 0.5 mg/kg p.o.. CI-1044 plasma levels increase proportionally with doses ranging between 0.1 and 40 mg/kg p.o. (R2=0.878). CI-1044 dose dependently inhibits the accumulation of eosinophils in Bronchoalveolar lavages (BAL) fluids with an ID 50 value of 3.25 mg/kg. A single dose treatment with CI-1044 (10 mg/kg, p.o.) 24, 8, 3 or 1 h before the antigen challenge induces 6, 56, 48 and 79% inhibition in the number of eosinophils in BAL.
197894-84-1 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-04-30 | HY-100246 | 1 mg | 1590 | ||
2024-04-30 | HY-100246 | 197894-84-1 | 197894-84-1 | 5mg | 3500 |